Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.48 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10211671 | 0.88 | MCHR1 (0.54) | MCHR1TAS1R3TAS1R1TAS1R2MAPT | |
| SCHEMBL10168991 | 0.86 | HRH3 (0.53) | MCHR1HRH3RAB9ASMN1; SMN2HPGD | |
| SCHEMBL10169066 | 0.84 | PKM (0.67) | MCHR1HRH3RAB9ASMN1; SMN2HPGD | |
| SCHEMBL10212614 | 0.81 | GRM5 (0.62) | HRH3KMT2AUSP30 | |
| SCHEMBL10168946 | 0.80 | HRH3 (0.52) | MCHR1HRH3RAB9ANPC1USP30 | |
| SCHEMBL10168947 | 0.80 | SMYD3 (0.55) | HRH3RAB9ASMN1; SMN2PKMNPC1 | |
| SCHEMBL13051465 | 0.79 | L3MBTL1 (0.64) | MCHR1RAB9ANPC1 | |
| SCHEMBL10210766 | 0.78 | HRH3 (0.58) | HRH3USP30SLC6A5 | |
| SCHEMBL10168938 | 0.78 | USP30 (0.52) | HRH3RAB9APKMNPC1USP30 | |
| SCHEMBL10168929 | 0.78 | USP30 (0.66) | HRH3RAB9APKMNPC1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | MCHR1 4816/4885HRH3 1169/4885TAS1R3 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.